Xerion Healthcare, an oncology spinout of University of Oxford’s Department of Engineering Science, has secured an undisclosed amount of funding from University of Oxford Isis Fund II.
Xerion aims to bring to market technology that uses nanoparticles for cancer therapy. Their tiny size enables chemotherapy drugs to be delivered directly to the tumour, reducing the harm done to the rest of the body. The nanoparticles can also be used to increase the efficiency of radiotherapy.
The technology is based on…
